|
Acton Pharmaceuticals, Inc. Submits NDA Supplement to FDA for AEROSPAN(R …
MarketWatch (press release) AEROSPAN is a hydrofluoroalkane (HFA) propelled inhaled corticosteroid for the treatment of asthma, which will compete in the $7 billion US inhaled steroid … |
View full post on asthma – Google News